Longitudial Study of SPIDDM

Studies in Longitudinal Evaluation of Slowly Progressing Type 1 Diabetes Mellitus

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051240223

Enrollment

Registered

2024-12-23

Start date

2025-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Slowly progressive insulin dependent (type 1) diabetes mellitus Type 1 Diabetes Mellitus

Interventions

PET imaging with the test drug 18F-labeled exendin-4.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with slowly progressive type 1 diabetes mellitus (probable) or suspected to have slowly progressive type 1 diabetes mellitus with positive islet-related autoantibodies.

Exclusion criteria

Exclusion criteria: Severe hepatic or renal dysfunction (AST>200U/L, ALT>200U/L, or eGFR<15mL/min/1.73m2) Use of GLP-1-related drugs that cannot be discontinued Unsuitable or contraindicated for Exenatide administration Alcohol, Tween 80, Metoclopramide and grucagon intolerance Other conditions that, in the judgment of the principal investigator/associate investigator, render the subject unsuitable for participation in this study

Design outcomes

Primary

Measure	Time frame
Pancreatic beta-cell mass	—

Secondary

Measure	Time frame
Insulin secretion capacity, blood glucose fluctuations	—

Contacts

Public ContactTakaaki Murakami

Kyoto University Hospital

tounaiei@kuhp.kyoto-u.ac.jp+81-75-751-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026